An efficient design for phase III studies of combination chemotherapies.

Suppr

超能文献

作者信息

Ellenberg S S, Eisenberger M A

出版信息

Cancer Treat Rep. 1985 Oct;69(10):1147-54.

PMID:4042093

Abstract

摘要

相似文献

An efficient design for phase III studies of combination chemotherapies.

Cancer Treat Rep. 1985 Oct;69(10):1147-54.

Factorial designs for randomized clinical trials.随机临床试验的析因设计

Cancer Treat Rep. 1985 Oct;69(10):1055-63.

Food and Drug Administration requirements for approval of new anticancer drugs.美国食品药品监督管理局对新型抗癌药物的批准要求。

Cancer Treat Rep. 1985 Oct;69(10):1155-9.

Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.响应面法与用于评估癌症化疗的临床试验设计

Cancer Treat Rep. 1985 Oct;69(10):1049-53.

Influence of measurement error on response rates.测量误差对响应率的影响。

Cancer Treat Rep. 1985 Oct;69(10):1127-32.

Size of phase III cancer clinical trials.III期癌症临床试验的规模。

Cancer Treat Rep. 1985 Oct;69(10):1087-93.

Design and analysis of controlled clinical trials in rheumatic diseases.

Clin Rheum Dis. 1983 Dec;9(3):499-514.

Strategy and alternate randomized designs in cancer clinical trials.癌症临床试验中的策略与交替随机设计

Cancer Treat Rep. 1982 May;66(5):1095-100.

Statistical concepts fundamental to investigations.调查的基本统计概念。

N Engl J Med. 1985 Apr 4;312(14):890-7. doi: 10.1056/NEJM198504043121405.

[Clinical experimental research in hematology: planning, data management and the presentation of the results].

Ter Arkh. 1996;68(7):65-72.

引用本文的文献

Design of Phase II Non-inferiority Trials.II期非劣效性试验的设计

Contemp Clin Trials Commun. 2017 Sep;7:23-27. doi: 10.1016/j.conctc.2017.04.008. Epub 2017 May 5.

Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.观点交锋：新诊断胶质母细胞瘤患者的随机对照与单臂II期临床试验

Neuro Oncol. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030.

Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.适应性临床试验：各种适应性设计要素的优缺点

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djx013.

Comparison of futility monitoring guidelines using completed phase III oncology trials.使用已完成的III期肿瘤学试验对无效性监测指南进行比较。

Clin Trials. 2017 Feb;14(1):48-58. doi: 10.1177/1740774516666502. Epub 2016 Sep 22.

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.二、三期生物标志物引导的适应性试验设计：方法学综述

PLoS One. 2016 Feb 24;11(2):e0149803. doi: 10.1371/journal.pone.0149803. eCollection 2016.

Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.创新临床试验设计：迈向21世纪医疗保健系统。

Stat Biosci. 2011 Dec;3(2):145-168. doi: 10.1007/s12561-011-9042-5.

The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.贝叶斯预测概率在临床试验中期监测中的效用。

Clin Trials. 2014 Aug;11(4):485-493. doi: 10.1177/1740774514531352. Epub 2014 May 28.

Integrated phase II/III clinical trials in oncology: a case study.肿瘤学中的整合 II/III 期临床试验：案例研究。

Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22.

Sequential design of phase II-III cancer trials.癌症 II-III 期临床试验的序贯设计。

Stat Med. 2012 Aug 15;31(18):1944-60. doi: 10.1002/sim.5346. Epub 2012 Mar 16.

Randomized phase II designs.随机II期设计。

Clin Cancer Res. 2009 Mar 15;15(6):1883-90. doi: 10.1158/1078-0432.CCR-08-2031. Epub 2009 Mar 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验